Raffel et al; Quantifying Cardiac Sympathetic Nerve Density S cintigraphic imaging of cardiac sympathetic innervation is an established noninvasive approach to assessing risk of sudden cardiac death in patients with heart failure and may be used to balance risks and benefits of implantable cardioverter defibrillator therapy. Evidence supporting this assertion has been building for almost 20 years, starting with small-scale trials using the sympathetic nerve imaging agent [ ]mIBG demonstrated that a single index of global cardiac sympathetic denervation, the heart-to-mediastinum ratio, was able to separate heart failure patients with high risk of sudden cardiac death from those with low risk. This finding has been remarkably consistent in subsequent trials with [ 123 I]mIBG in heart failure patients, using either planar scintigraphy or more advanced assessments with single-photon emission-computed tomography imaging, including the multicenter ADMIRE-HF trial (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure). 4 ,5 ADMIRE-HF confirmed that the heart-to-mediastinum ratio of [ 123 I]mIBG is an independent predictor of sudden cardiac death in heart failure patients and can be used to guide appropriate implantable cardioverter defibrillator therapy. 6 Further confirmation that regional cardiac sympathetic denervation promotes malignant arrhythmias comes from the recent PAREPET trial (Prediction of Arrhythmic Events with Positron Emission Tomography). 7, 8 This study used [ 11 C]-(-)-meta-hydroxyephredrine and positron-emission tomography (PET) to generate measures of the extent of regional cardiac sympathetic denervation in >200 heart failure patients staged for implantable cardioverter defibrillator placement. In addition, resting perfusion was measured using [ 13 N]ammonia, and myocardial viability was assessed using [ ]-(-)-meta-hydroxyephredrine retention) was found to be the strongest predictor of potentially fatal arrhythmic events. Subjects with denervation extent measures exceeding 37.4% of the left ventricle defined the upper tertile of patients at highest risk of sudden cardiac arrest. These results strongly suggest that PET-derived metrics of the regional extent of cardiac denervation provide an even stronger predictor of sudden cardiac death than the global heart-to-mediastinum ratio of [ ]-(-)-meta-hydroxyephredrine and irreversible neuronal retention through efficient trapping inside norepinephrine storage vesicles. We hypothesized that this combination of kinetic properties would make measures of their cardiac retention more sensitive in detecting the mild to moderate nerve losses that occur early in the progression of disease. In addition, their kinetics could be analyzed using tracer kinetic analysis methods previously applied to other irreversible cardiac radiotracers, such as [ 13 The purpose of this study was to perform first-inhuman assessments of [ 
CLINICAL PERSPECTIVE
Cardiac autonomic dysfunction can promote malignant arrhythmias, leading to sudden cardiac arrest. Recent clinical trials with radiolabeled sympathetic nerve imaging agents have established that higher levels of regional cardiac sympathetic denervation in heart failure are associated with a greatly elevated risk of ventricular arrhythmias and sudden death. These results point to a potential role of cardiac neuroimaging in improved sudden death risk stratification in heart failure patients being staged for placement of implantable cardioverter defibrillators. This study presents first-in-human studies of 2 new fluorine-18-labeled radiotracers developed for more accurate quantification of the extent of regional cardiac denervation using positron emission tomography. The findings show that these new radiotracers provide high-quality cardiac positron emission tomography images, are safe and well tolerated, and have human radiation dosimetry profiles comparable to existing positron emission tomography radiopharmaceuticals. In addition, their myocardial kinetics can be analyzed using Patlak graphical analysis to provide quantitative metrics of regional nerve density at high spatial resolution in the heart. Achieving similar results in patients with heart failure could ultimately allow one of these 2 radiotracers to be commercialized and distributed to positron emission tomography centers, with the goal of providing improved risk stratification for implantable cardioverter defibrillator therapy.
properties, metabolism, and kinetics in heart, liver, and blood. Patlak 
METHODS
The data, analytic methods, and study materials for this study are available from the corresponding author on reasonable request, contingent on compliance with applicable Health Insurance Portability and Accountability Act requirements and appropriate institutional review board approval. 
Study Design

Dynamic Cardiac PET Studies
A Siemens ECAT Exact HR+ PET camera was used for all studies. For the cardiac PET studies, a 90-minute dynamic sequence (12×10, 2×30, 2×60, 2×150, 2×300, and 7×600 s) was acquired after intravenous injection of [ 
Image Processing
Transaxial PET images were reoriented into orthogonal views, the short-axis images interpolated into 4-mm slices, and saved using the PMOD image analysis package (PMOD Technologies). These data were analyzed using a custom tracer kinetic analysis software package written in IDL (Harris Geospatial Solutions). On each of 16 short-axis slices, encompassing the left ventricle, an algorithm defined 60 angular sectors, centered on the left ventricular wall, generating 16×60=960 volumes of interest (VOIs). Time-activity curves for tissue, C t (t), were generated from the dynamic PET data for each VOI. Another VOI was placed in the left ventricular blood pool at the base of the heart to extract a whole-blood time-activity curve, C wb (t).
Input Functions
Blood samples were processed into purified plasma and analyzed on high-performance liquid chromatography (HPLC) system with an in-line radiation detector to determine the fraction of plasma activity associated with intact parent radiotracer, f intact (t). 11, 12 Whole-blood and plasma aliquots were counted in a gamma counter to determine the ratio of activity concentrations in plasma and whole-blood, C p /C wb . These data were used to convert the whole-blood curve C wb (t) to an intact tracer in plasma curve, C p (t), as C p (t)=C wb (t)·f intact (t)·[C p /C wb ]. Plasma curves were used as input functions for Patlak analysis. patient motion during the last 30 minutes caused artifacts in the time-activity data. In light of this, and considering that clinical studies with these tracers are unlikely to exceed 40 to 60 minutes, kinetic analyses used only the first 60 minutes of data. For Patlak analysis, the regional tissue time-activity curve C t (t) and the plasma time-activity curve C p (t) undergo mathematical transformations to generate a Patlak plot of the transformed data which has a distinct linear phase. 13 Linear regression of the linear portion of the plot provides a Patlak slope, K p (mL/min per gram), which is a measure of the rate of irreversible tracer uptake into sympathetic nerve terminals. Patlak analysis was performed using the myocardial kinetics of each VOI to determine regional values of the Patlak slope K p , the y intercept, and the linear regression coefficient R.
Tracer Kinetic Analysis
Biodistribution PET Studies and Radiation Dosimetry Estimates
Four whole-body PET scans were acquired, starting at 5, 60, 150, and 360 minutes after tracer injection. In some cases, the last 2 scans started at different times because of competing clinical responsibilities of the PET technologists. Human radiation dosimetry estimates were calculated using OLINDA/EXM Version 2.0 (Vanderbilt University, Hermes Medical Solutions) following published guidelines. [14] [15] [16] Briefly, whole-body PET scans were analyzed using the PMOD image analysis software suite to determine the total activity (kBq) in each organ of interest. Decay-corrected activity data were normalized to the total radiotracer dose injected (kBq) to determine the % injected dose (%ID) as a function of time for each organ. Biokinetic data for each organ were fit to a single exponential or biexponential clearance model using nonlinear regression analysis (GraphPad Prism, GraphPad Software). Uptake fractions and clearance half-times for each organ analyzed were entered into OLINDA/ EXM 2.0 to determine the number of disintegrations in the organ N i (MBq-h/MBq). In a few cases where tracer accumulation was evident in the early organ kinetics (eg, salivary glands), it was necessary to take an interpolated curve fit to the data and apply fluorine-18 decay factors to estimate the effective organ kinetics. This curve was then numerically integrated to directly determine N i (GraphPad Prism). The fraction of the injected dose eliminated by urinary excretion and the half-time for elimination were estimated from kinetic data for the bladder. The maximum fraction of the injected dose measured in the gastrointestinal tract was entered into the International Commission on Radiological Protection Human Alimentary Tract model incorporated into OLINDA/EXM 2.0, assuming the activity entered the small intestine. Each subject's biokinetic data were used to calculate radiation dosimetry estimates for the International Commission on Radiological Protection 89 adult male and adult female models. Dose estimates were averaged for each sex (n=4 each). The mean data for each sex were then averaged following International Commission on Radiological Protection 128 guidelines to obtain the final table of sex-averaged dose estimates. These values were multiplied by the appropriate tissue weighting factors and summed to determine the effective dose.
Safety and Tolerability Tests
Tests were performed to evaluate the safety of [ supine 12-lead ECG, body temperature, heart rate, and blood pressure were recorded, and blood and urine samples were collected. Laboratory tests included a comprehensive metabolic panel, complete blood count, plasma catecholamine levels, and urinalysis. For 90 minutes after radiotracer administration, heart rate and peripheral capillary oxygen saturation (SpO 2 ) were continuously monitored, and blood pressure was measured every 10 minutes. Female subjects took a urine pregnancy test before the PET session. Subjects were contacted 24 hours and 30 days after the PET session to enquire if they had experienced any adverse events related to the study.
Statistical Analyses
All presented data are mean±SD. Reported coefficients of variation (CV) were calculated as CV=(SD/mean)×100%. uptake of the tracers is similarly early, but [ 18 F]4F-MHPG clears more quickly than [ 18 F]3F-PHPG, affording better heart-to-liver contrast (2.4±0.4 versus 1.2±0.4, respectively). For both tracers, lung uptake was extremely low.
RESULTS
Safety
Dynamic Cardiac PET Studies
Blood Sample Analyses
Metabolism of [ Each tracer is metabolized into 1 major metabolite that is more polar than the parent compound (data not shown). Based on HPLC retention times, the metabolites formed in humans appear to be the same ones detected in preclinical PET studies in nonhuman primates. 11, 12 [ 18 F]4F-MHPG is metabolized by sulfate conjugation at the meta-hydroxyl position. 11 The metabolite of [
18 F]3F-PHPG remains unknown, but prior tests suggest that sulfate conjugation and glucuronidation are unlikely pathways. 12 Because highly linear Patlak plots were obtained in all subjects using plasma curves that excluded the [ 18 F]3F-PHPG radiometabolite, this strongly suggests that the radiometabolite is not transported into cardiac sympathetic nerves. Activity concentration ratios in plasma over whole-blood, C p (t)/C wb (t), were consistent in each study. Mean values of C p (t)/C wb (t) ranged from 1.29±0.14 to 1.38±0. 12 
Radiation Dosimetry Estimates
Maximum intensity projection images of whole-body PET scans are presented in Figure 7 . Each tracer exhibited high uptake and long retention times in the heart. The fraction of the injected dose (%ID) in the heart early after injection averaged 1 generated with the biokinetic data and OLINDA/EXM 2.0 are shown in Table 2 .
DISCUSSION
This report describes first-in-human PET studies of [
F]4F-MHPG and [
18 F]3F-PHPG, 2 new cardiac sympathetic nerve radiotracers. The results demonstrate that administration of these tracers is safe, their biodistribution is consistent with localization in peripheral tissues with dense sympathetic innervation, including the heart, and analysis of their myocardial kinetics can provide robust regional metrics of cardiac sympathetic nerve density.
An advantage of the irreversible kinetics of [ 18 F]4F-MHPG and [
18 F]3F-PHPG is the ability to use Patlak graphical analysis, a method developed for radiotracers with irreversible tissue kinetics. Because this approach uses linear regression of the Patlak plot data to estimate only 2 parameters (slope and intercept), it is possible to use smaller VOIs than would typically be used for other tracer kinetic analysis approaches, such as compartmental modeling. Although smaller VOIs have greater levels of statistical noise in the myocardial kinetic data, the Patlak approach can obtain robust regional nerve density measures at high spatial resolution. The Patlak slope is a measure of the net uptake or influx of tracer into irreversible tissue compartments, in this case, into the storage vesicles in sympathetic nerve terminals. Thus the regional value of the Patlak slope provides a useful quantitative metric of regional sympathetic nerve density. Our results showed that Patlak slopes K p had low CVs within subjects, as well as across subjects. This finding suggests that normal control databases of regional Patlak slopes can be used to quantitatively assess regional nerve losses in patients with heart diseases.
The Table 2 show that the urinary bladder wall is the critical organ, the organ receiving the highest radiation dose for these radiotracers. [17] [18] [19] [20] [21] have performed many pioneering studies of the impact of cardiovascular and neurological diseases on cardiac sympathetic nerve populations using 6-[ ]mIBG, was evaluated in normal human subjects, including biodistribution studies and human radiation dosimetry estimates. 22 Comparing radiation absorbed F]3F-PHPG into sympathetic neurons may be an advantage in accurately measuring low nerve densities in areas of severe denervation. Because each tracer possesses advantages over the other, they will be compared head-to-head in heart failure patients staged for implantable cardioverter defibrillator placement to determine which is better for clinical assessments of regional denervation in diseased hearts. In conclusion, the findings of these pilot studies in normal subjects suggest that [
18 F]3F-PHPG may represent a significant advance in our ability to precisely quantify the extent and severity of cardiac sympathetic denervation in heart diseases using PET. Future clinical studies in patients with a wide range of cardiac denervation levels, including heart failure patients, are required to confirm this conclusion. If they do, [ 
